Skip to main content

Table 1 Patient demographic characteristics

From: Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study

Characteristic

Group A

Group B

p-Value

 

(n = 42)

(n = 126)

 

Age (years) †

60.5 ± 8.5

60.2 ± 8.4

1.0

Male sex ‡

18 (42.9)

34 (42.9)

1.0

Genotype 1 ‡

25 (59.5)

75 (59.5)

1.0

Fatty liver ‡

12 (28.6)

60 (47.6)

0.03

Body weight (kg) †

61.7 ± 7.0

61.3 ± 10.3

0.75

Body mass index (kg/m 2 ) †

24.9 ± 2.5

24.6 ± 3.2

0.59

Necroinflammatory scores †

6.3 ± 2.0

6.0 ± 1.9

0.31

Creatinine (mg/dL) †

0.9 ± 0.3

0.9 ± 0.6

0.81

AST (U/L) †

99.2 ± 43.8

94.4 ± 62.8

0.65

ALT (U/L) †

119.8 ± 62.4

137.1 ± 103.6

0.197

AFP (ng/mL) †

45.5 ± 96.4

16.9 ± 42.6

0.08

Albumin (g/dL) †

3.8 ± 0.5

4.2 ± 0.4

0.001

Total bilirubin (mg/dL) †

1.2 ± 0.5

1.0 ± 0.4

0.03

White blood cell s (×10 3 /μL) †

5.5 ± 1.9

5.8 ± 1.7

0.33

Hemoglobin level (g/dL) †

13.5 ± 1.8

14.2 ± 1.6

0.03

Platelet count (×10 3 /μL) †

129.6 ± 47.3

177.0 ± 54.7

<0.001

HCV RNA (IU/mL) †

1.81 ± 2.00 ×106

1.53 ± 6.90 ×106

0.67

Low viral load ‡

14 (33.3)

45 (35.7)

0.78

rs8099917 (TT) ‡

33/40 (82.5)

110/124 (88.7)

0.307

rs12979860 (CC) ‡

34/40 (85)

114/126 (90.5)

0.332

Ribavirin per body weight (mg/kg) †

15.7 ± 2.9

16.3 ± 2.7

0.19

  1. HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, α-fetoprotein.
  2. Low viral load, HCV RNA ≤800,000 IU/mL.
  3. †mean ± SD; ‡no. (%).
  4. Group A, patients with Ishak fibrosis score 4–6.
  5. Group B, patients with Ishak fibrosis score 0–3.